LogicBio Therapeutics has joined the list of biotechs to go public this year but it had to cut the price of its IPO and sell more shares to pull it off.... Read more »
Novartis has agreed to pay $2.1 billion cash to acquire Endocyte, expanding an ongoing effort by the Swiss firm to develop targeted radiation treatments for cancer.
Under the agreement, Novartis... Read more »
AbbVie is positioning itself to add fibrosis drugs to its pipeline through a new research and development partnership with startup Morphic Therapeutics.
Under the agreement, AbbVie (NYSE: ABBV) will pay... Read more »
[Updated 10/17/18, 2:52 p.m. See below.] Express Scripts has just exerted its influence over the emerging market battle between drug makers trying to sell a new class of migraine-preventing... Read more »
Warp Drive Bio started up in 2012 with a potential buyer, Sanofi, already in place. Six years later the Cambridge, MA, company is being acquired—by another startup, Revolution Medicines.
The companies... Read more »
Roche, the world’s biggest cancer drug company, selected the technology of startup SQZ Biotechnologies to help it develop new cellular therapies for cancer. Three years after that drug alliance started,... Read more »
The number of biotech companies completing an IPO has swelled this year and Adynxx aims to join their ranks—but through an alternate path. The pain drug developer has agreed to combine... Read more »
Allogene Therapeutics has raised $288 million in an IPO, marking one of the biggest stock market debuts for a biotech this year.
The cell therapy developer sold 18.4 million shares at... Read more »
Biotech startups in the Hoosier State now have a new source of funding for innovations at the early stage of development.
BioCrossroads on Wednesday announced a $9 million seed fund.... Read more »
[Corrected, 10/11/18, 11:12 a.m.] The FDA has lifted its hold on a clinical trial for a genetically engineered treatment for sickle cell disease, and CRISPR Therapeutics and Vertex Pharmaceuticals... Read more »
Glympse Bio has developed sensor technology that it says can give clinicians an early look at a developing disease. As Glympse prepares to test its disease detection approach in a serious... Read more »
A Menlo Therapeutics drug developed to treat chronic cough has failed to beat a placebo in a mid-stage study, and the clinical-stage company is stopping work on that drug program.
It’s... Read more »
Cancer immunotherapy is all the rage these days. The idea of harnessing the immune system to treat cancer has sparked billions of dollars in research, led to a vast matrix of... Read more »
Guardant Health continued the rapid drumbeat of life science IPOs this year by raising $237.5 million in its stock market debut, making it one of the biggest IPOs so far this... Read more »
Yesterday was a good day for Paratek Pharmaceuticals.
The FDA approved a Paratek antibiotic as a treatment for pneumonia and serious skin infections. That regulatory decision late Tuesday for the drug,... Read more »
Applying fertilizers to fields has been a standard farming practice for generations. The problem with these chemicals is that they end up in the air or in water runoff. Scientists at... Read more »
VelosBio, a biotech startup researching new cancer drugs, has raised $58 million in financing.
The new VelosBio cash, a Series A round of financing, was led by Arix Bioscience (LSE: ARIX... Read more »
[Updated, 9/28/18, 12:54 p.m. See below.] An Eli Lilly drug developed to prevent migraine headache pain before it starts has won FDA approval.
The FDA decision announced late... Read more »
The window for life science IPOs is still open, and five biotechs and one medical device company chose the last week of the third quarter to make their stock market debuts.... Read more »
Eli Lilly has a blockbuster diabetes drug, dulaglutide (Trulicity), which helps the body make more insulin. But that drug, and others in the same class, are injectables. A number of companies... Read more »